We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KGX:XETRKION GROUP AG Analysis

Data as of 2026-06-19 - not real-time

€41.84

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

KION GROUP AG trades at €41.84, comfortably above its 20‑day SMA (≈€41.26) but still well under the 50‑day (≈€43.73) and 200‑day (≈€55.04) averages, signaling a short‑term technical bounce within a broader bearish backdrop. The MACD histogram is positive and the line sits above its signal, offering a *bullish* cue, while the RSI hovers around 50, suggesting no immediate over‑bought or over‑sold condition. Fundamentally, the stock appears **undervalued** – its trailing P/E of ~15 is less than half the industry average of 31, and the DCF‑derived fair value of €53.75 implies roughly 40 % upside. The price‑to‑book ratio of 0.88 places the market below book value, and a dividend yield of 1.5 % with a modest 29 % payout ratio points to a *sustainable* dividend. However, the balance sheet is leveraged (debt‑to‑equity ≈128 %) and 30‑day volatility exceeds 44 %, flagging notable risk.
The recent earnings call highlighted an improving order intake and a rise in adjusted EBIT margin to 7.4 %, supporting a *growth‑value blend* narrative. Analyst consensus remains optimistic (median target €59, “buy” rating) and the Fear‑Greed Index sits at “Extreme Greed,” indicating market enthusiasm. Investors should weigh the upside potential against high leverage, sector cyclicality, and elevated price swings when forming a position.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at €35.80
  • Bullish MACD histogram suggests short‑term upside
  • High 30‑day volatility raises downside risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value indicates ~40 % upside
  • Improving EBIT margins and order intake
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Price below book value (P/B 0.88) offers a margin of safety
  • Undervalued relative to peers (P/E ~15 vs industry ~31)
  • Global footprint diversifies revenue streams despite leverage

Key Metrics & Analysis

Financial Health

Revenue Growth-0.60%
Profit Margin3.26%
P/E Ratio14.9
ROE6.14%
ROA2.28%
Debt/Equity127.55
P/B Ratio0.9
Op. Cash Flow€1.1B
Free Cash Flow€1.1B
Industry P/E31.4

Technical Analysis

TrendBearish
RSI50.0
Support€35.80
Resistance€46.26
MA 20€41.26
MA 50€43.73
MA 200€55.04
MACDBullish
VolumeIncreasing
Fear & Greed Index90.61

Valuation

Fair Value€53.75
Target Price€58.67
Upside/Downside40.23%
GradeUndervalued
TypeBlend
Dividend Yield1.50%

Risk Assessment

Beta0.02
Volatility44.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.